SG11201408243VA - Compositions and methods for enhancing the efficacy of contraceptive microbicides - Google Patents

Compositions and methods for enhancing the efficacy of contraceptive microbicides

Info

Publication number
SG11201408243VA
SG11201408243VA SG11201408243VA SG11201408243VA SG11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA SG 11201408243V A SG11201408243V A SG 11201408243VA
Authority
SG
Singapore
Prior art keywords
international
compositions
efficacy
methods
contraceptive
Prior art date
Application number
SG11201408243VA
Other languages
English (en)
Inventor
Wendell Guthrie
Original Assignee
Evofem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201408243V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evofem Inc filed Critical Evofem Inc
Publication of SG11201408243VA publication Critical patent/SG11201408243VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
SG11201408243VA 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides SG11201408243VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261659368P 2012-06-13 2012-06-13
PCT/US2013/032510 WO2013187984A1 (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Publications (1)

Publication Number Publication Date
SG11201408243VA true SG11201408243VA (en) 2015-01-29

Family

ID=49758600

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408243VA SG11201408243VA (en) 2012-06-13 2013-03-15 Compositions and methods for enhancing the efficacy of contraceptive microbicides

Country Status (17)

Country Link
US (7) US20150202216A1 (enExample)
EP (2) EP3308771A1 (enExample)
JP (2) JP6352907B2 (enExample)
KR (1) KR102062599B1 (enExample)
CN (2) CN104487054A (enExample)
AP (1) AP2014008149A0 (enExample)
AU (2) AU2013274815B2 (enExample)
BR (1) BR112014030984B1 (enExample)
EA (1) EA201590008A1 (enExample)
HK (1) HK1208809A1 (enExample)
IL (1) IL235812B (enExample)
MX (2) MX365905B (enExample)
NZ (1) NZ703203A (enExample)
SG (1) SG11201408243VA (enExample)
UA (1) UA115876C2 (enExample)
WO (1) WO2013187984A1 (enExample)
ZA (1) ZA201500111B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6352907B2 (ja) * 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法
RU2691950C1 (ru) * 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
EP3522879A4 (en) * 2016-10-04 2020-06-03 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis
USD920853S1 (en) * 2018-09-14 2021-06-01 Porsche Lizenz—und Handelsgesellschaft mbH & Co. KG Bicycle
US11850303B2 (en) 2020-10-27 2023-12-26 Uqora, Inc. Gel and a suppository and methods to provide the gel and suppository
IL313241A (en) * 2021-12-02 2024-07-01 Communitreat Ltd Composition of sterilants, kits, and methods of using them

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1213323B (it) * 1986-08-07 1989-12-20 Crinos Industria Farmaco Composizione per uso locale ad atti vita' spermicida virulicida ,disinfettante e/o battericida
US4999342A (en) 1988-08-16 1991-03-12 Ortho Pharmaceutical Corporation Long lasting contraceptive suppository composition and methods of use
JP3202365B2 (ja) 1992-12-04 2001-08-27 株式会社紀文フードケミファ オリゴマンヌロン酸を重合度によって分離する方法
US5592949A (en) 1994-06-29 1997-01-14 Moench; Thomas R. Device for acidic buffering and method for inactivation of pathogens
US5667492A (en) * 1994-10-07 1997-09-16 Columbia Laboratories, Inc. Use and composition of an anti-sexually transmitted diseases formulation
FR2728464B1 (fr) 1994-12-22 1997-04-30 Innothera Lab Sa Forme galenique unitaire, son procede d'obtention et ses utilisations
US6093394A (en) 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
WO2001038284A1 (en) 1999-11-24 2001-05-31 Cargill Dow Llc Improved lactic acid processing; methods; arrangements; and, products
AU2001243431B2 (en) * 2000-03-07 2006-05-25 Rush University Medical Center Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JP2009102407A (ja) 2001-03-08 2009-05-14 Rohto Pharmaceut Co Ltd Ｇリッチなアルギン酸含有組成物
US20020177624A1 (en) 2001-03-16 2002-11-28 Calvin Hanna Acetate-lactate buffering vaginal gel and for method of making same and treating bacterial vaginosis
ITMI20010913A1 (it) 2001-05-04 2002-11-04 Univ Pavia Composizioni a rilascio controllato di acido lattico a livello vaginale
JP2004537525A (ja) 2001-06-11 2004-12-16 メルク　エンド　カムパニー　インコーポレーテッド ＰＰＡＲδアゴニストの投与による炎症性疾患の治療法
US20060105008A1 (en) 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US20130150810A1 (en) 2002-04-30 2013-06-13 The Population Council, Inc. Intravaginal ring for the delivery of unique combinations of antimicrobial compositions
JP4712380B2 (ja) 2002-07-26 2011-06-29 三笠製薬株式会社 外用剤
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
EP1635847B1 (en) 2003-06-13 2019-07-31 IDH Holding ApS Treatment of symptoms associated with bacterial vaginosis
US20050272700A1 (en) 2004-05-10 2005-12-08 Servet Buyuktimkin Topical treatment and prevention of human papilloma virus (HPV) infection
RU2257197C1 (ru) 2004-05-12 2005-07-27 Дулькис Мария Дмитриевна Вагинальные суппозитории, обладающие контрацептивным действием
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20100069323A1 (en) 2006-11-10 2010-03-18 Rohto Pharmaceutical Co., Ltd. Composition for application to skin or mucosa
US7659259B2 (en) 2006-12-21 2010-02-09 Bausch & Lomb Incorporated Method of treating inflammation of the eye
BRPI0809330B8 (pt) 2007-03-30 2021-05-25 Laccure Ab uso de um ou mais oligômeros de ácido láctico, e, composição farmacêutica
AU2008256689A1 (en) * 2007-05-24 2008-12-04 New York Blood Center Inc. Rapidly dispersible vaginal tablet that provides a bioadhesive gel
WO2009003189A1 (en) 2007-06-27 2008-12-31 Acresso Software, Inc. A method and system for software virtualization directly from an installation package
TW200927141A (en) 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
CA2721457A1 (en) * 2008-04-16 2009-10-22 Cipla Limited Topical combinations comprising an antimycotic agent and an antiviral agent
CN101559036B (zh) * 2008-04-18 2012-02-08 上海医药工业研究院 一种阴道用避孕凝胶组合物及其制备方法和应用
WO2009155118A1 (en) 2008-05-30 2009-12-23 Reprotect, Inc. Compositions and methods for inactivation of pathogens at genital tract surfaces
EP2130531A1 (en) 2008-06-04 2009-12-09 Rolf Kullgren AB Vaginal suppository comprising lactic acid
BRPI0803568B8 (pt) * 2008-08-14 2021-05-25 Biolab San Us Farm Ltda composição mucoaderente
US20120070476A1 (en) 2009-05-29 2012-03-22 Moench Thomas R Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces
EP2440560A1 (en) 2009-06-10 2012-04-18 Ultimorphix Technologies B.v. The succinate of tenofovir disoproxil
EP2704694A4 (en) 2011-05-02 2014-11-19 Aptalis Pharmatech Inc RAPID DISSOLUTION TABLET COMPOSITIONS FOR VAGINAL DELIVERY
AU2012275292B2 (en) 2011-06-28 2015-11-12 Chemo Research, S.L. High dosage mucoadhesive metronidazole aqueous-based gel formulations their use to treat bacterial vaginosis
EP2827854A1 (en) 2012-03-19 2015-01-28 Dr. August Wolff GmbH & Co. KG Arzneimittel Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
JP6352907B2 (ja) 2012-06-13 2018-07-04 イボフェム， インコーポレイテッド 避妊殺菌剤の効果を増強するための組成物および方法
US20150246065A1 (en) 2012-09-14 2015-09-03 Cipla Limited Topical Pharmaceutical Composition
WO2015027071A1 (en) 2013-08-21 2015-02-26 Georgia Regents Research Institute, Inc. Gpr81 agonists and methods thereof for promoting production of secretory iga
WO2015070072A1 (en) 2013-11-07 2015-05-14 Evofem, Inc. Methods for manufacturing contraceptive microbicides with antiviral properties
RU2691950C1 (ru) 2013-12-19 2019-06-19 Ивофем, Инк. Композиции и способы ингибирования воспаления и заболеваний с применением антимикробного соединения на основе альгиновой кислоты
US9801839B2 (en) 2014-02-28 2017-10-31 Macfarlane Burnet Institute For Medical Research And Public Health Pty Ltd Therapeutic method
US20190209502A1 (en) 2016-09-12 2019-07-11 Evofem, Inc. Combination gel for sexually transmitted infections
EP3522879A4 (en) 2016-10-04 2020-06-03 Evofem, Inc. Method of treatment and prevention of bacterial vaginosis

Also Published As

Publication number Publication date
UA115876C2 (uk) 2018-01-10
US20200147015A1 (en) 2020-05-14
AP2014008149A0 (en) 2014-12-31
NZ703203A (en) 2016-07-29
MX2019007176A (es) 2019-08-16
MX365905B (es) 2019-06-18
JP2015519395A (ja) 2015-07-09
US9566232B2 (en) 2017-02-14
AU2017206199B2 (en) 2019-03-28
IL235812A0 (en) 2015-01-29
US10568855B2 (en) 2020-02-25
EP3308771A1 (en) 2018-04-18
WO2013187984A1 (en) 2013-12-19
EP2861215A1 (en) 2015-04-22
JP6352907B2 (ja) 2018-07-04
EP2861215A4 (en) 2015-04-22
CN104487054A (zh) 2015-04-01
US20190133978A1 (en) 2019-05-09
ZA201500111B (en) 2016-01-27
AU2013274815A1 (en) 2015-01-22
CN110693812A (zh) 2020-01-17
EA201590008A1 (ru) 2015-05-29
AU2017206199A1 (en) 2017-08-03
US11439610B2 (en) 2022-09-13
US11992472B2 (en) 2024-05-28
US20150202216A1 (en) 2015-07-23
US20160008276A1 (en) 2016-01-14
US20230241013A1 (en) 2023-08-03
KR102062599B1 (ko) 2020-01-06
KR20150018636A (ko) 2015-02-23
BR112014030984B1 (pt) 2022-05-24
JP2018109034A (ja) 2018-07-12
MX2014015307A (es) 2015-07-06
US20240423936A1 (en) 2024-12-26
AU2013274815B2 (en) 2017-04-20
BR112014030984A2 (pt) 2017-06-27
JP6738573B2 (ja) 2020-08-12
HK1208809A1 (en) 2016-03-18
IL235812B (en) 2020-05-31
US20170128396A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201408174UA (en) Antibody formulation
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201811549UA (en) Boronic acid derivatives and therapeutic uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407200TA (en) Liquid formulation
SG11201408133TA (en) Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201408509PA (en) Racecadotril lipid compositions
SG11201407536UA (en) Topical pharmaceutical compositions comprising terbinafine and urea
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201907159SA (en) Treatment of hidradenitis suppurativa
SG11201805755SA (en) Methods of administering hepcidin
SG11201407599SA (en) Oligonucleotide chelate complex-polypeptide compositions and methods
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201907153RA (en) Topical formulations and methods
SG11201906226YA (en) Methods of treating bacterial infections
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction
SG11201804048WA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201811351WA (en) Compositions and methods for forming stable, liquid metal oxide/hydroxide formulations
SG11201810701XA (en) Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein